

Medicines for Europe joins the Antimicrobial (AMR) One Health Network

For immediate release

Date of release: 09 May 2023

Medicines for Europe is pleased to announce the appointment of Boumediene Soufi, Global Head of AMR at Sandoz, as its expert representative in the Antimicrobial Resistance One Health Network. Antimicrobial resistance is a major public health threat that requires strong policies to mitigate its global spread.

Medicines for Europe members manufacture and supply most antibiotic medicines and we are committed to fighting AMR by:

- investing in areas of unmet medical needs through established antibiotic medicines to improve the management of risks such as sepsis.
- developing standards with the [AMR Industry Alliance](#) to reduce the environmental footprint of manufacturing, ensure responsible access and appropriate use.
- engaging with EU authorities (HERA, EMA) to reduce the risk of shortages, which can accelerate the spread of AMR, and to create more sustainable market models for antibiotic medicines.

Speaking on his appointment, Boumediene Soufi said *“I am very honoured and greatly looking forward to collaborating with the EU and relevant stakeholders to take legislative and policy initiatives to the next level, in line with our common goal of acting across sectors to reduce the spread of AMR. I see many opportunities for significant improvements in this critical domain of public health policy, particularly in the closely related areas of responsible use, responsible access, and responsible manufacturing. Let’s act together now to optimise the use of antibiotics, reduce the risk of shortages, and help to ensure a sustainable market model for the supply of these essential medicines.”*

Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on Twitter [@medicinesforEU](#).